



3.4.5 Nephrology Group

Publications:20 | **Q1:**13

COMPOSITION

María Gemma Fernández Juárez.
Jefa de Servicio en Nefrología. Hospital Universitario La Paz

- **María José Castro Notario.** Enfermera. Hospital Universitario La Paz
- **Olga Costero Fernández.** Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz
- **Gloria del Peso Gilsanz.** Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz
- **María Elena González García.** Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz
- **Carlos Jiménez Martín.** Jefe de Sección de Nefrología. Hospital Universitario La Paz
- **María Ovidia López Oliva.** Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz
- **Almudena Pérez Torres.** Dietista-Nutricionista. Hospital Universitario Santa Cristina
- **Begoña Rivas Becerra.** Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz
- **Amir Shabaka Fernández.** Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz
- **Rafael Jesús Sánchez Villanueva.** Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz

STRATEGIC OBJETIVES

- The strategic objective of this care-research group is to enable, by developing a deep understanding of the various components that make up nephrology (kidney diseases in initial stages, progression of kidney disease, particular and general complications of dialysis and kidney transplantation), access by affected patients to the best diagnostic and therapeutic interventions available at any time. Each of the areas must ensure a minimum level of research and development activity representing the innovation in these areas. The lines of research are at times cross-sectional to the four components indicated for overall nephrology

RESEARCH LINES

1. Glomerular nephropathies:
 - Role of PLA2r levels in membranous nephropathy.
 - Study of the alternative pathway of complement in glomerular pathologies: vasculitis, membranous nephropathy, IgA glomerulonephritis...
 - Morbidity, mortality and progression of diabetic nephropathy and other glomerular nephropathies.
 - Adult polycystic kidney disease. Family studies and therapeutic approaches.
 - Association between cardiovascular disease and progression of nephropathies (NEFRONA multicenter studies).
2. Renal replacement therapy:
 - Evolution of peritoneal function in peritoneal dialysis. Implications for patient and technique survival. New peritoneal dialysis devices and solutions. Aquaporin 1 and its genetic polymorphisms. Involvement of alternatively activated macrophages and CC
 - Cardiovascular risk in dialysis patients. Study of endocrine alterations in dialysis patients. Role of FGF 21 in uremic insulin resistance.
 - Mouse model for peritoneal dialysis: exploration of the effects of dialysis fluids, pharmacological interventions and genetic manipulation (KO, transgenic).
3. Complications of renal transplantation.
 - Infection and CMV disease in renal transplantation. Personalized treatment.
 - Graft tolerance.



- Quality of life of the transplanted patient. Patient-reported transplant outcome.
- Individualization of immunosuppression.
- Knowledge of graft cortical microcirculation.
- Continuous active collaboration with the Spanish renal transplant group (SENTRA), some led by the La Paz group: Covid disease, renal prevention (iSGLT-2), pregnancy in renal transplantation, bacterial infections, thrombotic microangiopathy, asystole donation, relapses of different renal diseases after transplantation...



3.4 Large System Pathologies Area

RESEARCH ACTIVITY

Doctoral theses

- **Tejera Muñoz A.** El factor 2 de la red de comunicación celular (CCN2) ejerce un papel esencial en el mantenimiento de la estructura y las respuestas vasculares de la aorta en ratones.[dissertation]. *Madrid: UAM: 2023(24/03/2023). Director: Ruiz Ortega M, Rodríguez Díez, R.*

Publications

- **Anders HJ, Fernández-Juárez GM, Vaglio A, Romagnani P, Floege J.** CKD therapy to improve outcomes of immune-mediated glomerular diseases. *Nephrol Dial Transpl.* 2023; 8(Supplement 2): ii50-ii57. Article. IF: 4.8; Q1
- **Aresté N, Sánchez-Álvarez JE, Prieto-Velasco M, Molina P, Esteve-Simó V, Ojeda R, Buades JM, Goicoechea M, Sánchez-Villanueva R, Bezhoid GA, Pérez-Morales RE, Santos AB, Peiró-Jordan R, Arenas MD.** Prevalence and severity of pruritus in Spanish patients with chronic kidney disease and impact on quality of life: a cross-sectional study. *Clin Kidney J.* 2023; 16(6): 1035-7. Letter. IF: 3.9; Q1
- **Caravaca-Fontán F, Caverio T, Díaz-Encarnación M, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juárez G, Rodríguez A, de José AP, Rabasco C, Rodado R, Fernández L, Pérez-Gómez V, Avila A, Bravo L, Espinosa N, Allende N, de la Nieta MDS, Rodríguez E, Rivas B, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, González F, Shabaka A, López-Rubio ME, Fenollosa MA, Martín-Penagos L, Da Silva I, Titos JA, de Córdoba SR, de Jorge EG, Praga M.** Clinical profiles and patterns of kidney disease progression in c3 glomerulopathy. *Kidney360.* 2023; 4(5): 659-72. Article. IF: 3.2; Q1
- **Esteve-Simó V, Pérez-Morales R, Buades-Fuster JM, Jiménez MDA, Areste-Fosalba N, Bezhoid GA, Santos AB, Álvarez ES, Villanueva RS, Molina P, Ojeda R, Prieto-Velasco M, Goicoechea M.** Chronic kidney disease-associated pruritus and quality of life: learning from

our patients. *J Clin Med.* 2023; 12(13): 4505. Review. IF: 3.0; Q1

- **Fernández-Juárez G, Ronco P, Jha V.** Personalized treatment of PLA2R-related membranous nephropathy. *Clin J Am Soc Nephro.* 2023; 18(4): 530-2. Editorial Material. IF: 8.5; D1
- **Fructuoso AIS, Raba AB, Deras EB, Sánchez LAV, San Cecilio RV, Esteve AF, Vega LC, Martínez E, García ME, Coronado PS, Morales NDV, Larrondo SZ, Cano NR, Blanca AM, Marrero DH, Castello IB, Ramos JP, Ochoa AS, Molas CF, Roncero FG, Ramírez AT, Guldriis SC, Flores IP.** Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study. *Clin Kidney J.* 2023; 6(16): 1022-34. Article. IF: 3.9; Q1
- **Goicoechea M, Arenas-Jiménez MD, Areste N, Pérez-Morales RE, Esteve V, Sánchez-Álvarez E, Bezhoid GA, Blanco A, Sánchez-Villanueva R, Molina P, Ojeda R, Prieto-Velasco M, Buades JM.** Perception of spanish nephrologists on an old unsolved problem: pruritus associated with chronic kidney disease (CKD-aP). *Nefrologia.* 2023; 43(1): 102-10. Article. IF: 2.0; Q2
- **Hilhorst M, Bemelman EJ, Bruchfeld A, Fernández-Juárez GM, Floege J, Frangou E, Goumenos D, van Kooten C, Kronbichler A, Stevens KI, Turkmen K, Wiersinga WJ, Anders HJ.** Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG). *Nephrol Dial Transpl.* 2023; 38(8): 1807-16. Article. IF: 4.8; Q1
- **López-Oliva MO, Pérez-Flores I, Molina M, Aladrén MJ, Trujilloe H, Redondo-Pachón D, López V, Facundo C, Villanego F, Rodríguez M, Ruiz MC, Antón P, Rivas-Oural A, Cabello S, Portolés J, de la Vara L, Tabernero G, Valero R, Galeano C, Moral E, Ventura A, Coca A, Nuñez MA, Hernández-Gallego R, Shabaka A, Ledesma G, Bouarich H, Rodríguez MA, Tamajón LP, Cruzado L, Sánchez JE, Jiménez C.** Management of immunosuppressive therapy in kidney transplant recipients with COVID-19. A multicentre national study derived from the Spanish Society of Nephrology. COVID registry. *Nefrologia.* 2023; 43(4): 442-51. Article. IF: 2.0; Q2
- **Mazuecos A, Villanego F, Alonso A, Beneyto I, Crespo M, Díaz-Corte C, Franco A, González-Roncero F, Guirado L, Jiménez C, Juega J, Llorente S, Paul J, Rodríguez-Benot A, Ruiz JC, Sánchez-Fructuoso A, Torregrosa V, Rodrigo E, Hernández D, López V, López-Oliva M, Zarraga S.** Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients. *Nefrologia.* 2023; 43(5): 531-45. Review. IF: 2.0; Q2
- **Molina P, Ojeda R, Blanco A, Alcalde G, Prieto-Velasco M, Areste N, Buades JM, Esteve-Simó V, Goicoechea M, Pérez-Morales RE, Sánchez-Álvarez E, Villanueva RS, Arenas MD.** Etiopathogenesis of chronic kidney disease-associated pruritus: Putting the pieces of the puzzle together. *Nefrologia.* 2023; 43(1): 48-62. Article. IF: 2.0; Q2
- **Moura MC, Gauckler P, Anders HJ, Bruchfeld A, Fernández-Juárez GM, Floege J, Frangou E, Goumenos D, Segelmark M, Turkmen K, van Kooten C, Tesar V, Geetha D, Fervenza FC, Jayne DRW, Stevens K, Kronbichler A.** Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations. *Nephrol Dial Transpl.* 2023; 38(11): 2637-51. Review. IF: 4.8; Q1
- **Pérez-Torres A, Caverni-Muñoz A, García EG.** Mediterranean diet and chronic kidney disease (CKD): A practical approach. *Nutrients.* 2023; 15(1): 97. Article. IF: 4.8; Q1
- **Rojas-Rivera JE, García-Carro C, Avila A, Espino M, Espinosa M, Fernández-Juárez G, Fulladosa X, Goicoechea M, Macía M, Morales E, Quintana LF, Praga M.** Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN). *Clin Kidney J.* 2023; 16(9): 1384-402. Review. IF: 3.9; Q1
- **Rojas-Rivera JE, García-Carro C, Ávila AI, Espino M, Espinosa M, Fernández-Juárez G, Fulladosa X, Goicoechea M, Macía M, Morales E, Porras LFQ, Praga M.** Consensus document of

the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis. *Nefrologia.* 2023; 43(1): 17319. Review. IF: 2.0; Q2

- **Santos-Alonso C, Gallardo MAV, Bermejo MF, López-Oliva MO, Ramos SA, García EG, Mancheno JCS, Fernández EG, Soraluze NI, Martín CJ.** Multicentric Castleman's disease in kidney transplant: A case report and literature review. *Nefrologia.* 2023; 43: 102-4. Letter. IF: 2.0; Q2
- **Santos-Alonso C, Rivas B, Vega-Cabrera C, Arenzana CB, Gregorio LY, Riaño MA, Fernández EG, Rubio MAB.** Congenital porto-systemic shunt: An uncommon cause of membranoproliferative glomerulonephritis. *Nefrologia.* 2023; 43: 118-20. Letter. IF: 2.0; Q2
- **Sanz KA, Parente CE, Ferreras C, Ribes MM, Navarro A, Mestre C, Clares L, Vicario JL, Balas A, De Paz R, Granados EL, Zapardiel ES, Jiménez C, López-Oliva M, Ramos E, Hernández-Oliveros F, Pérez-Martínez A.** Familial CD45RA- T cells to treat severe refractory infections in immunocompromised patients. *Front Med (Lausanne).* 2023; 10: 1083215. Article. IF: 3.1; Q1
- **Sevillano AM, Caravaca-Fontán F, García-Galan LC, Fernández-Juárez G, López-Reuelta K, Guzmán DA, Martín-Reyes G, Quintana LF, Rodas LM, de la Nieta MDS, Rabasco C, Espinosa M, Díaz-Encarnación M, San Miguel L, Barrios C, Rodríguez E, García P, Valera A, Peña JK, Shabaka A, Velo M, Sierra M, González F, Fernández-Reyes MJ, Heras M, Delgado P, Gutiérrez E, Moreno JA, Praga M.** Effect of immunosuppressive treatments on kidney outcomes after gross hematuria-related acute kidney injury in older patients with iga nephropathy. *Kidney Int Rep.* 2023; 8(8): 1596-604. Article. IF: 5.7; D1
- **Tato AM, Carrera N, García-Murias M, Shabaka A, Avila A, Mora MTM, Rabasco C, Soto K, Álvarez EJD, Fernández-Lorente L, Rodríguez-Moreno A, Huerta A, Mon C, García-Carro C, Cabrera FG, Navarro JAM, Romero A, Gutiérrez E, Villacorta J, de Lorenzo A, Avilés B, Garca-González MA, Fernández-Juárez G.** Genetic testing in focal segmental glomerulosclerosis: to whom and when? *Clin Kidney J.* 2023; 16(11): 2011-22. Article. IF: 3.9; Q1



Research projects

- **del Peso Gilsanz, Gloria.** Clinical validation of a continuous flow peritoneal dialysis system, with dialysate regeneration (CORDIAL). UE. 2020-2024. *Managment centre: FIBHULP*
- **del Peso Gilsanz G.** Relación de la funcionalidad de la membrana peritoneal y la patología cardiovascular en pacientes en diálisis peritoneal tratados con soluciones biocompatibles. repercusión sistémica de un problema local (PI22/00574). ISCIII. 2023-2025. *Managment centre: FIBHULP*
- **del Peso Gilsanz, Gloria.** Las células mesoteliales del efluente crecidas ex vivo reflejan las alteraciones peritoneales encontradas en la biopsia peritoneal. Oportunidades adicionales para biomarcadores en el efluente. Fundación SENEPRO. 2016-Ongoing. *Managment centre: FIBHULP*
- **Fernández Juárez GM.** Aproximación diagnóstica y terapéutica de las microangiopatías trombóticas. Alexion Pharma Spain S.L. 2022-Ongoing. *Managment centre: FIBHULP*
- **Fernández Juárez GM.** Descifrando el papel de factor h-related proteins en las enfermedades renales relacionadas con complemento (PI19/01695). ISCIII. 2020-2023. *Managment centre: FIBHULP*
- **Fernández Juárez GM.** Nefropatías asociadas con desregulación del complemento: estudio genético y de proteínas para determinar facto-

res de riesgo y de progresión de daño renal (PI-2749). SEN. 2023-Ongoing. *Managment centre: FIBHULP*

- **González García ME.** Prevalencia de fragilidad en pacientes con enfermedad renal crónica en lista de espera de trasplante renal en España: un estudio multicéntrico. SET. 2022-2023. *Managment centre: FIBHULP*
- **Jiménez Martín C.** Desarrollo y aplicación de un programa grupal de atención psicológica basada en las preferencias y valores con el objetivo de mejora de resultados en salud en el paciente con trasplante renal. Astellas Pharma, S.A. 2018-Ongoing. *Managment centre: FIBHULP*
- **Jiménez Martín C.** Evaluación de la microcirculación cortical del trasplante renal a largo plazo medida por ecografía con contraste y su correlación histopatológica por biopsia renal. Sociedad Madrileña de Trasplantes. 2019-Ongoing. *Managment centre: FIBHULP*
- **Sánchez Villanueva R.** Abordaje nutricional en pacientes con enfermedad renal. Fresenius Kabi España S.A.U. 2021-Ongoing. *Managment centre: FIBHULP*
- **Sánchez Villanueva R.** Creación de un centro de referencia para el estudio de los mecanismos implicados en las reacciones de hipersensibilidad a las membranas de hemodialis basadas en polysulfona. Nipro Europe Nv. 2017-Ongoing. *Managment centre: FIBHULP*



3. Information groups by area

3.4 Large System Pathologies Area

Cibers and Retics

- **RD21/0005/0018 Bajo Rubio MA.** Inflamación e inmunopatología de órganos y sistemas. ISCIII. (31/12/2024). FIBHULP
- **RD21/0005/0030 Fernández Juárez GM.** Inflamación e inmunopatología de órganos y sistemas. ISCIII. (31/12/2024). FIBHULP

Clinical trials

- **Del Peso Gilsanz G.** A study to evaluate the efficacy and safety of xylocore, a glucose sparing experimental solution, for peritoneal dialysis.
Type/Phase: III
Sponsored by: Iperboreal Pharma, S.R.L
Signed date: 13/11/2023
- **Del Peso Gilsanz G.** Seguimiento de las trayectorias de tratamiento en pacientes adultos con hiperpotasemia (track). estudio longitudinal, prospectivo y no intervencionista de la evolución del tratamiento de pacientes adultos con hiperpotasemia.
Type/Phase: EOm prospectivo
Sponsored by: Astrazeneca Ab
Signed date: 24/01/2023
- **Del Peso Gilsanz G.** Seguimiento de las trayectorias de tratamiento en pacientes adultos con hiperpotasemia (track). estudio longitudinal, prospectivo y no intervencionista de la evolución del tratamiento de pacientes adultos con hiperpotasemia.
Type/Phase: EOm prospectivo
Sponsored by: Astrazeneca Ab
Signed date: 28/09/2023
- **Sánchez Villanueva RJ.** A phase 3 randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of dose-titrated pls240 in the treatment of secondary hyperparathyroidism in individuals with end stage kidney disease on hemodialysis (path-1) with an open-label extension.
Type/Phase: III
Sponsored by: Pharmaceutical Product Development Spain, S.L.
Signed date: 10/10/2023

- **Sánchez Villanueva RJ.** Relief census: estudio transversal para evaluar la prevalencia y la carga del prurito urémico en pacientes que se someten a hemodiálisis.
Type/Phase: No EPA
Sponsored by: Vifor Pharma- Vifor International Inc
Signed date: 12/05/2023

Patents and trademarks

- **Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees.** Use of compounds derived from salts of pyridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.
- **Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees.** Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.
- **López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R, Passlickdeetjen J. Buechel J, Steppan S, inventors; Fresenius Medical Care AG & Co. KGaA, assignee.** Method and kit for diagnosing epithelial to mesenchymal transition of the peritoneum (EMT-Chip). WO2017042253, DE102015115158; 2015 September 09.
- **Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J, inventors; Fresenius Medical Care Deutschland GMBH, assignee.** Pharmaceutical compositions containing steviosides. PCT/EP2015/074955, EP3212199, US2017304335, CN107073022; 2014 October 31.